Reimbursed Care Access in Armenia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine (intranasal SPRAVATO®) does not appear on publicly available Armenian lists of approved medicines and there is no evidence of a national marketing approval or public reimbursement program for esketamine in Armenia; therefore it is not available as a routinely reimbursed therapy and would only be accessible through an imported/compassionate-use pathway or an approved clinical trial if such were authorized. Armenian circulation and authorization of medicines are governed by the Law on Medicines and the Ministry of Health processes; import/export and special authorization procedures for narcotic/psychotropic products are administered by the Controlled Substances Management Department. # #

Ketamine is an established anesthetic agent and is controlled but medically authorized in Armenia for standard anesthetic and related clinical indications; it is managed under Armenia’s narcotics/psychotropic regulation and medicine circulation framework administered by the Ministry of Health and the Controlled Substances Management Department. The Law on Medicines and the national 'List of Narcotic Drugs, Psychotropic Substances and Their Precursors Subject to Control' set the legal and administrative framework for ketamine’s medical circulation and import/export authorizations. # #

Clinical/psychiatric use (e.g., subanesthetic IV ketamine for treatment‑resistant depression) would be off‑label in Armenia and, based on available public information about Armenian reimbursement and essential medicines lists, is not covered by public reimbursement schemes; such uses would typically be delivered in private clinical settings under physician discretion and institutional approval, with procurement and documentation handled according to narcotics control procedures (import/wholesale licensing and recordkeeping). The national essential medicines and reimbursement framework is determined by Ministry of Health orders and the national formulary/essential medicines lists; ketamine as an anesthetic is part of routine hospital formularies but off‑label psychiatric protocols lack explicit public funding guidance. # #

Regional/state nuance: Armenia is a unitary state (no federal/state reimbursement differences); any variance in access is provider/institutional (public hospital formulary vs private clinic) rather than subnational legal differences. Physicians seeking to use ketamine for psychiatric indications should follow national licensing, narcotics handling rules, and institutional ethics/approval processes.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as containing controlled psychotropic constituents (DMT) and therefore treated as a controlled substance under Armenian law; there is no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #